0001477932-26-001481
SEC filingQuantum Genesis AI Corp. (fka Quantumzyme Corp., QTZM) reported no sales for the quarter ended January 31, 2026, consistent with prior periods, resulting in a loss from operations of $1,382. The primary driver of the net loss of $4,329,657 was a $4,325,872 loss on conversion of debt, alongside $2,403 interest expense, leading to total other expenses of $4,328,275. This compares to a net loss of $29,806 in the prior year quarter, marking a significant deterioration primarily due to the one-time debt settlement charge. For the six months ended January 31, 2026, net loss widened to $4,379,525 from $89,329 YoY, again driven by the debt conversion loss. Balance sheet shows minimal cash of $59 and total assets of $59, with total liabilities of $418,401 exceeding assets, yielding stockholders' deficit of $418,342. Net cash used in operations was $43,810 for the six months, partially offset by $43,285 from financing via notes payable. The company raises substantial going concern doubts due to ongoing losses and funding dependency. No revenue generation or segment operations disclosed; focus remains on financing needs amid ineffective internal controls.
Quantum Genesis AI Corp. (fka Quantumzyme Corp.) reported zero sales for the quarter ended January 31, 2026, matching the prior year quarter. Operating expenses fell to $1,382 from $24,534 YoY, primarily due to lower professional fees including a $18,029 credit. Loss from operations was $1,382 versus $24,534 YoY. Other expenses surged to $4,328,275 from $5,272, driven by $4,325,872 loss on debt conversion and $2,403 interest. Net loss reached $4,329,657 ($0.12 per share) from $29,806 ($0.00 per share) YoY. For six months, net loss was $4,379,525 ($0.11 per share) versus $89,329 ($0.00 per share). Balance sheet reflects cash $59, total assets $59, liabilities $418,401, and stockholders' deficit $418,342 as of January 31, 2026, compared to prior July 31, 2025 figures of cash $584, assets $584, liabilities $441,301, deficit $440,717.
No revenues reported for the quarter or six months ended January 31, 2026, unchanged from prior year periods. The company has no disclosed operating segments and operates as a single reportable segment. Management notes dependency on future financing rather than revenue generation, with historical focus on asset acquisition in enzyme catalyst sector but no current sales activity.
No gross margin applicable due to zero revenue. Operating loss of $1,382 reflects minimal expenses. Profitability severely impacted by non-operating loss on debt conversion of $4,325,872, where 2,010,000 common shares valued at $4,401,900 settled $60,300 notes and $15,728 interest. Accumulated deficit grew to $10,016,092 from $5,636,567 at July 31, 2025.
For six months, net cash from operations was -$43,810, adjusted for $4,325,872 non-cash debt loss, with changes in accounts payable +$10,243 and due to related party -$400. Financing provided $43,285 from notes payable. Net cash decrease $525, ending at $59. Balance sheet shows critical liquidity with $59 cash, no prepaid expenses, offset by $169,733 accounts payable, $16,602 related party dues, $232,066 notes payable. Working capital deficit $418,342 signals high insolvency risk.
Management highlights going concern doubts from $4.4M six-month loss, $10M accumulated deficit, and $43.8K cash burn. Dependent on securities sales or external funding with no firm agreements. Expects operating expenses to rise with activity but provides no quantitative guidance. Risks include dilution from equity raises, ineffective controls due to limited resources and segregation issues, and no audit committee. Name change to Quantum Genesis AI Corp. effective February 11, 2026.